These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

818 related items for PubMed ID: 15528407

  • 21. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.
    Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Wilton SD.
    J Gene Med; 2006 Feb; 8(2):207-16. PubMed ID: 16285002
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, van Ommen GJ, van Deutekom JC, Aartsma-Rus A.
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.
    Aartsma-Rus A, Kaman WE, Weij R, den Dunnen JT, van Ommen GJ, van Deutekom JC.
    Mol Ther; 2006 Sep; 14(3):401-7. PubMed ID: 16753346
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles.
    Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, Jadoon A, Bou-Gharios G, Partridge T.
    Proc Natl Acad Sci U S A; 2005 Jan 04; 102(1):198-203. PubMed ID: 15608067
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Modification of pre-mRNA processing: application to dystrophin expression.
    Wilton SD, Fletcher S.
    Curr Opin Mol Ther; 2006 Apr 04; 8(2):130-5. PubMed ID: 16610765
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Rescue of a dystrophin-like protein by exon skipping normalizes synaptic plasticity in the hippocampus of the mdx mouse.
    Dallérac G, Perronnet C, Chagneau C, Leblanc-Veyrac P, Samson-Desvignes N, Peltekian E, Danos O, Garcia L, Laroche S, Billard JM, Vaillend C.
    Neurobiol Dis; 2011 Sep 04; 43(3):635-41. PubMed ID: 21624465
    [Abstract] [Full Text] [Related]

  • 35. Noninvasive monitoring of therapeutic gene transfer in animal models of muscular dystrophies.
    Bartoli M, Poupiot J, Goyenvalle A, Perez N, Garcia L, Danos O, Richard I.
    Gene Ther; 2006 Jan 04; 13(1):20-8. PubMed ID: 16107863
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy.
    Takeshima Y, Yagi M, Wada H, Ishibashi K, Nishiyama A, Kakumoto M, Sakaeda T, Saura R, Okumura K, Matsuo M.
    Pediatr Res; 2006 May 04; 59(5):690-4. PubMed ID: 16627883
    [Abstract] [Full Text] [Related]

  • 38. U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping.
    Brun C, Suter D, Pauli C, Dunant P, Lochmüller H, Burgunder JM, Schümperli D, Weis J.
    Cell Mol Life Sci; 2003 Mar 04; 60(3):557-66. PubMed ID: 12737315
    [Abstract] [Full Text] [Related]

  • 39. Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino.
    Wu B, Lu P, Benrashid E, Malik S, Ashar J, Doran TJ, Lu QL.
    Gene Ther; 2010 Jan 04; 17(1):132-40. PubMed ID: 19759562
    [Abstract] [Full Text] [Related]

  • 40. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
    Popplewell LJ, Graham IR, Malerba A, Dickson G.
    Methods Mol Biol; 2011 Jan 04; 709():153-78. PubMed ID: 21194027
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.